NCT02726568 - High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2022

Conditions

Non-small Cell Lung CancerBrain Metastases

Interventions

DRUG

Icotinib

375 mg Tid (1125 mg per day) until intracranial PD.

RADIATION

SRS

If intracranial PD, then the subjects get stereotatic radiosurgery （30Gy/3f) combined with Icotinib 375mg Tid.

Trial Locations (1)

RECRUITING

West China Hospital, Chengdu